LINCOLN

Lincoln Pharmaceuticals Share Price

 

 

Invest in Lincoln Pharmaceuticals with 2.94X leverage

Invest with MTF
Lincoln Pharmaceuticals live price: ₹617.65. It opened at ₹611 vs previous close ₹622; intraday high/low: ₹625/₹611. The 50 & 200 DMA stand at ₹560.33/₹548.06.

Lincoln Pharmaceuticals Performance

  • Low
  • ₹611
  • High
  • ₹625
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹677
  • Open Price₹611
  • Previous Close₹622
  • Volume29,968
  • 50 DMA₹560.33
  • 100 DMA₹541.16
  • 200 DMA₹548.06

Investment Returns

  • Over 1 Month + 16.79%
  • Over 3 Month + 30.13%
  • Over 6 Month + 10.55%
  • Over 1 Year + 18%

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.1
  • PEG Ratio
  • -8.2
  • Market Cap Cr
  • 1,237
  • P/B Ratio
  • 1.7
  • Average True Range
  • 25.39
  • EPS
  • 43.85
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 30.35
  • RSI
  • 60.8
  • MFI
  • 61.28

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹617.65
-4.2 (-0.68%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹602.64
  • 50 Day
  • ₹560.33
  • 100 Day
  • ₹541.16
  • 200 Day
  • ₹548.06

Resistance and Support

617.85 Pivot Speed
  • R3 638.60
  • R2 631.75
  • R1 624.70
  • S1 610.80
  • S2 603.95
  • S3 596.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 651.94 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 19% and 17% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-13 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.1.80 per share(18%)Final Dividend
View Lincoln Pharmaceuticals Dividend History Arrow

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
4.7%
36.28%
9.24%

About Lincoln Pharmaceuticals

  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹617 As on 12 March, 2026 | 22:15

The Market Cap of Lincoln Pharmaceuticals is ₹1237.1 Cr As on 12 March, 2026 | 22:15

The P/E ratio of Lincoln Pharmaceuticals is 14.1 As on 12 March, 2026 | 22:15

The PB ratio of Lincoln Pharmaceuticals is 1.7 As on 12 March, 2026 | 22:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23